CDMOs/CMOs Ramp Up Biomanufacturing Capacity

Capital investments are ramping up in biomanufacturing, which continues to be an active area for CDMOs/CMOs in both traditional biologics and new modalities. Which companies are expanding? For the text version of this article visit dcatvci.org.

Key topics: (see Chapter Markers in drop down menu in audio player above)

• A roundup of expansion activity
• Fujifilm Diosynth Biotechnologies
• Samsung Biologics
• Lonza
• Boehringer Ingelheim
• Thermo Fisher Scientific
• Catalent
• WuXi Biologics

 Sponsor: BIOVECTRA

Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Support the show 

Support the show